← Sino Medical Sciences Technology In overview

Sino Medical Sciences Technology In vs Imeik Technology Development: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sino Medical Sciences Technology In (688108.CG)

Q3 202624 Jul – 9 Oct 2026

▲4

Sino Medical's profit surge and overseas approvals drive the story

First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.

August 202624 Jul – 9 Oct 2026

▲4

Sino Medical's profit surge and overseas approvals drive the story

First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.

Latest24 Jul – 9 Oct 2026

▲4

Sino Medical's profit surge and overseas approvals drive the story

First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.

Imeik Technology Development Co (300896.CS)

Q3 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

August 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

Latest15 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.